View Older Stories View More Recent Stories

Nov 30, 2017 07:08AM Merck (MRK) Announces New, Updated Data for its KEYTRUDA and Updated Data on LYNPARZA in Multiple Breast Cancer Subtypes to Be Presented at SABCS
Nov 30, 2017 07:00AM New and Updated Data for Merck’s KEYTRUDA® (pembrolizumab) and Updated Data on LYNPARZA® (olaparib) in Multiple Breast Cancer Subtypes to Be Presented at the 2017 San Antonio Breast Cancer Symposi
Nov 29, 2017 07:00AM Impassioned Lung Cancer Survivors Join Your Cancer Game Plan, Merck to Advocate for Others Facing This Highly Stigmatized Disease
Nov 28, 2017 02:33PM Merck Announces Increased Quarterly Dividend and $10 Billion Share Repurchase Authorization
Nov 28, 2017 08:10AM Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients with Pre-Treated Advanced Gastric Cancer
Nov 28, 2017 08:04AM Merck (MRK) and Pfizer (PFE) Announce Phase III JAVELIN Gastric 300 Study in Patients With Pre-Treated Advanced Gastric Cancer Did Not Meet Primary Endpoint
Nov 28, 2017 08:00AM Merck and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients With Pre-Treated Advanced Gastric Cancer
Nov 14, 2017 06:55AM Merck Announces Final Results of Any and All Tender Offers
Nov 13, 2017 02:00PM Merck Announces Pricing of Any and All Tender Offers
Nov 13, 2017 10:10AM Trump taps ex-pharma executive Azar as U.S. health secretary
Nov 13, 2017 08:01AM Merck (MRK) Receives Positive CHMP Opinion for PREVYMIS in European Union
Nov 13, 2017 08:00AM Merck Receives Positive CHMP Opinion for PREVYMIS™ (letermovir) in the European Union
Nov 9, 2017 06:46AM Merck (MRK) Announces FDA Approval of PREVYMIS for Prevention of CMV Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients
Nov 9, 2017 06:45AM Merck Receives FDA Approval of PREVYMIS™ (letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients
Nov 7, 2017 04:00AM Merck's Consumer Health Leads Debate on Preparing Gen Z for 100 Healthy Years
Nov 6, 2017 05:00PM Merck Animal Health Introduces Care & Control of Pet Diabetes To Help Pet Owners Deal with the Disease
Nov 6, 2017 08:56AM Merck Announces Any and All Tender Offers
Nov 2, 2017 09:00AM Merck Publishes Annual Corporate Responsibility Report
Nov 1, 2017 09:00AM Merck Animal Health Introduces Care & Control of Pet Diabetes To Help Pet Owners Deal with the Disease
Oct 27, 2017 04:18PM Merck (MRK) Withdraws European Application for KEYTRUDA in Combination with Pemetrexed and Carboplatin for First-Line Treatment of NSCLC
Oct 27, 2017 04:17PM Merck Provides Update on European Application for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Carboplatin for First-Line Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
Oct 27, 2017 06:45AM Merck Announces Third-Quarter 2017 Financial Results
Oct 23, 2017 08:30PM Corning to Showcase Latest in Pharmaceutical Glass Technologies at CPhI Worldwide in Frankfurt, Germany
Oct 23, 2017 06:59AM Merck (MRK) & AstraZeneca PLC (AZN) Report Second Regulatory Submission to Rapidly Advance LYNPARZA (olaparib) in Japan
Oct 23, 2017 06:55AM AstraZeneca and Merck Rapidly Advance LYNPARZA® (olaparib) in Japan With a Second Regulatory Submission
Oct 23, 2017 05:47AM Merck (MRK) Announces Data from Real-World Study Shows ZEPATIER (Elbasvir and Grazoprevir)
Oct 21, 2017 02:00PM Real-World Study Shows ZEPATIER® (Elbasvir and Grazoprevir) Resulted in High Rates of Sustained Virologic Response in Patients with Chronic Hepatitis C Infection Who Have Chronic Kidney Disease
Oct 18, 2017 07:01AM Merck (MRK) and AstraZeneca (AZN) Granted FDA Acceptance of Regulatory Submission for LYNPARZA (Olaparib)
Oct 18, 2017 06:55AM U.S. FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review
Oct 18, 2017 06:47AM Merck (MRK) Says KEYTRUDA More Than Doubled Median Overall Survival Compared to Chemotherapy After Two Years of Follow Up in First-Line Treatment of Patients with Metastatic NSCLC with High Levels of
Oct 18, 2017 06:45AM Merck’s KEYTRUDA® (pembrolizumab) More Than Doubled Median Overall Survival Compared to Chemotherapy After Two Years of Follow Up in First-Line Treatment of Patients with Metastatic Non-Small Cell
Oct 12, 2017 01:00PM Merck Makes $3 Million Charitable Donation to Support Swim Across America
Oct 12, 2017 06:55AM Merck Joins with the American Liver Foundation to Educate U.S. Veterans on Chronic Hepatitis C Virus (HCV) Infection
Oct 11, 2017 04:47PM Merck (MRK) Says it Won't Submit Applications for Regulatory Approval for Anacetrapib
Oct 11, 2017 04:45PM Merck Provides Update on Anacetrapib Development Program
Oct 10, 2017 08:04AM Merck (MRK) Announces Six-year Efficacy Data for GARDASIL 9 Presented at EUROGIN 2017 Congress
Oct 10, 2017 08:00AM Six-year Efficacy Data for GARDASIL® 9 Presented at EUROGIN 2017 Congress
Oct 4, 2017 08:05AM Merck (MRK) Reports 40 Data Presentations at ID Week 2017
Oct 4, 2017 08:00AM Merck Highlights Ongoing Commitment to Fighting Infectious Diseases With 40 Data Presentations at ID Week 2017
Oct 3, 2017 06:58AM Merck (MRK) to Present New Data on ZEPATIER for Treatment of Chronic HCV Infection at The Liver Meeting
Oct 3, 2017 06:55AM Merck to Present New Data on ZEPATIER® (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Infection at The Liver Meeting® 2017
Sep 29, 2017 06:57AM Merck (MRK) to Discontinue MK-3682B and MK-3682C Development Programs for HCV
Sep 29, 2017 06:56AM Merck (MRK) Says New and Updated Data on KEYTRUDA to Be Presented at WCLC
Sep 29, 2017 06:55AM Merck Discontinues MK-3682B and MK-3682C Development Programs
Sep 29, 2017 06:55AM New and Updated Clinical Data on Merck’s KEYTRUDA® (pembrolizumab) to Be Presented at 18th World Conference on Lung Cancer
Sep 28, 2017 09:00AM Merck Animal Health Extends Commitment to Fighting Rabies in the World’s Most At-Risk Regions
Sep 27, 2017 06:45AM Merck to Hold Third-Quarter 2017 Sales and Earnings Conference Call on October 27
Sep 22, 2017 03:32PM Merck (MRK) Says FDA Approves KEYTRUDA for Recurrent Metastatic Gastric or GEJ Cancer Whose Tumors Express PD-L1
Sep 22, 2017 03:30PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Whose Tumors Express PD-L1 (
Sep 21, 2017 06:23AM Merck KGaA, Pfizer (PFE) Report European Commission Approval for Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
View More Recent Stories View Older Stories